Table 2.
Overall survival and progression-free survival with or without biliary drainage by treatment arm
| BD (n = 34) | Non-BD (n = 49) | |||
|---|---|---|---|---|
| GC arm (n = 16) | G arm (n = 18) | GC arm (n = 25) | G arm (n = 24) | |
| Overall survival | ||||
| 1-year survival rate | 40.9% | 27.8% | 37.8% | 33.3% |
| Median survival time (months) | 11.3 | 8.1 | 9.6 | 7.5 |
| Hazard ratio (95% confidence interval) | 0.588 (0.266–1.301) | 0.758 (0.397–1.447) | ||
| Progression-free survival | ||||
| 6-month progression-free survival | 53.3% | 27.8% | 43.7% | 27.5% |
| Median progression-free survival (months) | 7.1 | 3.9 | 4.5 | 3.3 |
| Hazard ratio (95% confidence interval) | 0.479 (0.222–1.032) | 0.748 (0.407–1.374) | ||
BD, biliary drainage; G arm, gemcitabine monotherapy; GC arm, combination therapy with gemcitabine and cisplatin.